Lv1
70 积分 2025-08-04 加入
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
9个月前
已完结
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
9个月前
已完结
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
9个月前
已完结
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
10个月前
已完结
Mechanisms of hepatic stellate cell activation
10个月前
已完结
Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling
10个月前
已完结
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m6A-regulated expression of a novel anti-fibrotic target ETV4
10个月前
已完结
Esculin inhibits hepatic stellate cell activation and CCl4-induced liver fibrosis by activating the Nrf2/GPX4 signaling pathway
10个月前
已完结
Restoration of Sinusoid Fenestrae Followed by Targeted Nanoassembly Delivery of an Anti‐Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis
10个月前
已完结
["Multi-component-multi-target-multi-pathway" mechanism of Kuihua Hugan Tablets based on network pharmacology]
10个月前
已完结
皖公网安备34019202002308
